Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Kent Osborne

Showing results (71-80 of 158) with videos related to

Pageof 16
Sort By:
Journal of the National Cancer Institute|March 6, 2003
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancerC Kent Osborne, Valerie Bardou, Torsten A Hopp, et al.
Cancer Cell|December 13, 2006
Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancerLi Hua Wang, Xiao Yi Yang, Xiaohu Zhang, et al.
Breast Cancer Research and Treatment|March 17, 2005
Consensus statement: Expedition Inspiration 2004 Breast Cancer Symposium 'Breast Cancer--The Development and Validation of New Therapeutics'Marc E Lippman, Chris Benz, Arul Chinnaiyan, et al.
NPJ Breast Cancer|December 5, 2018
Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancerCristina Guarducci, Martina Bonechi, Matteo Benelli, et al.
Lancet (London, England)|August 9, 2003
Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancerJenny C Chang, Eric C Wooten, Anna Tsimelzon, et al.
The New England Journal of Medicine|July 4, 2003
Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancerMartin S Tallman, Robert Gray, Nicholas J Robert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2011
Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II studyC Kent Osborne, Patrick Neven, Luc Y Dirix, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2007
Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313)Hannah M Linden, Charles M Haskell, Stephanie J Green, et al.
Journal of the National Cancer Institute|December 18, 2003
Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumorsChunhua Lu, Corey Speers, Yun Zhang, et al.
Breast Cancer Research and Treatment|May 31, 2012
Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapiesAlbert C Chen, Ilenia Migliaccio, Mothaffar Rimawi, et al.
Pageof 16

Showing results (71-80 of 158) with videos related to

Sort By:
Pageof 16
Journal of the National Cancer Institute|March 6, 2003
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancerC Kent Osborne, Valerie Bardou, Torsten A Hopp, et al.
Cancer Cell|December 13, 2006
Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancerLi Hua Wang, Xiao Yi Yang, Xiaohu Zhang, et al.
Breast Cancer Research and Treatment|March 17, 2005
Consensus statement: Expedition Inspiration 2004 Breast Cancer Symposium 'Breast Cancer--The Development and Validation of New Therapeutics'Marc E Lippman, Chris Benz, Arul Chinnaiyan, et al.
NPJ Breast Cancer|December 5, 2018
Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancerCristina Guarducci, Martina Bonechi, Matteo Benelli, et al.
Lancet (London, England)|August 9, 2003
Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancerJenny C Chang, Eric C Wooten, Anna Tsimelzon, et al.
The New England Journal of Medicine|July 4, 2003
Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancerMartin S Tallman, Robert Gray, Nicholas J Robert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2011
Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II studyC Kent Osborne, Patrick Neven, Luc Y Dirix, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2007
Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313)Hannah M Linden, Charles M Haskell, Stephanie J Green, et al.
Journal of the National Cancer Institute|December 18, 2003
Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumorsChunhua Lu, Corey Speers, Yun Zhang, et al.
Breast Cancer Research and Treatment|May 31, 2012
Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapiesAlbert C Chen, Ilenia Migliaccio, Mothaffar Rimawi, et al.
Pageof 16